Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease TRAVELESS

BACKGROUND AND AIMS: Subcutaneous SC vedolizumab presents the opportunity for inflammatory bowel disease IBD patients to manage their treatment at home. There are currently no data on the process of transitioning patients established on intravenous IV to SC vedolizumab as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC, at 12 weeks following the transition. METHODS: In all, 178 adult patients were offered the opportunity to transition to SC vedolizumab. Patients who agreed were reviewed prior to switching and at Week 12 W12 after their first SC dose. Evaluation outcomes included disease activity scores, the IBD-Control Patient-Reported Outcome Measures PROMs, and faecal calprotectin FCP. Reasons for patients declining or accepting transitioning, pharmacokinetics, adverse drug reactions, and risk factors for a poor outcome in SARS-CoV-2 infection were also assessed. RESULTS: A total of 124 patients agreed to transition, of whom 106 patients had been on IV vedolizumab for at least 4 months. There were no statistically significant differences in disease activity scores or IBD-Control PROMs between baseline and W12. A statistically significant increase in FCP was observed 31 µg/g vs. 47 µg/g; p = 0.008, although this was unlikely to be clinically relevant. The most common adverse drug reaction reported was injection site reactions 15%. Based on this cohort of patients, an expected reduction of £572,000 per annum is likely to be achieved. CONCLUSIONS: Transitioning patients established on IV vedolizumab to SC appears to be safe and effective, with high patient satisfaction and multiple benefits for the health service.